Picterus Jaundice mHealth platform Bringing newborn care home: An integral mHealth solution for neonatal jaundice management.
- Coordinator
- Picterus AS, Norway
- Runs
- 1 September 2023 to 31 August 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.9m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190162545
What the project is doing
In the project's own words, from its summary on CORDIS.
Neonatal jaundice (NNJ) affects 60%-80% of newborns worldwide (84-112 million/year). Ten percent will develop severe jaundice (SNJ), which can cause permanent brain damage or even death (114,000 newborns die/year, 75,000 suffer severe long-term neurological impairments). A fast, point-of-care, affordable method for NNJ screening and monitoring in the first 2 weeks of life is crucial, but current methods are insufficient (e.g. visual assessment, transcutaneous device, blood test).
Health systems face increasing pressure on their resources. It is imperative to develop more sustainable models of care and empower patients and their families. Picterus is developing the first digital platform to enable NNJ screening by parents and caregivers at home, and a timely referral to healthcare services. Our recommendation tool will allow families to monitor NNJ at home with their smartphones, and healthcare workers to efficiently manage a greater number of families by avoiding unnecessary visits.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Picterus AS | Trondheim | Norway | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI